NICE scopes Alexza's Adasuve for schizophrenia
This article was originally published in Scrip
Alexza Pharmaceuticals' schizophrenia treatment Adasuve (loxapine) will shortly be up for review by NICE, the health technology appraisal institute for England and Wales. The institute has put the draft version of the scope of the review out for consultation.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.